Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin

Cláudia Gomes; Sandra Martínez-Puchol; Noemí Palma; Gertrudis Horna; Lidia Ruiz-Roldán; Maria J. Pons; Joaquim Ruiz

doi:10.3109/1040841X.2015.1136261

Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin

Cláudia Gomes, Sandra Martínez-Puchol, Noemí Palma, Gertrudis Horna, Lidia Ruiz-Roldán, Maria J. Pons, Joaquim Ruiz

Medicina humana

Research output: Contribution to journal › Review article › peer-review

103 Scopus citations

Abstract

From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing, both in human and veterinary medicine. Although initially designed to the treatment of Gram-positive microorganisms, this antimicrobial family has also been used to treat specific Gram-negative bacteria. Some of them, as azithromycin, are considered in the armamentarium against Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms of macrolide resistance, currently described in Enterobacteriaceae.

Original language	English
Pages (from-to)	1-30
Number of pages	30
Journal	Critical Reviews in Microbiology
Volume	43
Issue number	1
DOIs	https://doi.org/10.3109/1040841X.2015.1136261
State	Published - 2 Jan 2017

Keywords

23S rRNA
esterases
methylases
phospotransferases
ribosomal mutations

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/1040841X.2015.1136261

Cite this

@article{cfa1273ab01e4cfe9c7d4c6baeaf4be7,

title = "Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin",

abstract = "From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing, both in human and veterinary medicine. Although initially designed to the treatment of Gram-positive microorganisms, this antimicrobial family has also been used to treat specific Gram-negative bacteria. Some of them, as azithromycin, are considered in the armamentarium against Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms of macrolide resistance, currently described in Enterobacteriaceae.",

keywords = "23S rRNA, esterases, methylases, phospotransferases, ribosomal mutations",

author = "Cl{\'a}udia Gomes and Sandra Mart{\'i}nez-Puchol and Noem{\'i} Palma and Gertrudis Horna and Lidia Ruiz-Rold{\'a}n and Pons, {Maria J.} and Joaquim Ruiz",

note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = jan,

day = "2",

doi = "10.3109/1040841X.2015.1136261",

language = "Ingl{\'e}s",

volume = "43",

pages = "1--30",

journal = "Critical Reviews in Microbiology",

issn = "1040-841X",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Macrolide resistance mechanisms in Enterobacteriaceae

T2 - Focus on azithromycin

AU - Gomes, Cláudia

AU - Martínez-Puchol, Sandra

AU - Palma, Noemí

AU - Horna, Gertrudis

AU - Ruiz-Roldán, Lidia

AU - Pons, Maria J.

AU - Ruiz, Joaquim

PY - 2017/1/2

Y1 - 2017/1/2

N2 - From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing, both in human and veterinary medicine. Although initially designed to the treatment of Gram-positive microorganisms, this antimicrobial family has also been used to treat specific Gram-negative bacteria. Some of them, as azithromycin, are considered in the armamentarium against Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms of macrolide resistance, currently described in Enterobacteriaceae.

AB - From its introduction in 1952 onwards, the clinical use of macrolides has been steadily increasing, both in human and veterinary medicine. Although initially designed to the treatment of Gram-positive microorganisms, this antimicrobial family has also been used to treat specific Gram-negative bacteria. Some of them, as azithromycin, are considered in the armamentarium against Enterobacteriaceae infections. However, the facility that this bacterial genus has to gain or develop mechanisms of antibiotic resistance may compromise the future usefulness of these antibiotics to fight against Enterobacteriaceae infections. The present review is focused on the mechanisms of macrolide resistance, currently described in Enterobacteriaceae.

KW - 23S rRNA

KW - esterases

KW - methylases

KW - phospotransferases

KW - ribosomal mutations

UR - http://www.scopus.com/inward/record.url?scp=85008487984&partnerID=8YFLogxK

U2 - 10.3109/1040841X.2015.1136261

DO - 10.3109/1040841X.2015.1136261

M3 - Artículo de revisión

C2 - 27786586

AN - SCOPUS:85008487984

SN - 1040-841X

VL - 43

SP - 1

EP - 30

JO - Critical Reviews in Microbiology

JF - Critical Reviews in Microbiology

IS - 1

ER -

Macrolide resistance mechanisms in Enterobacteriaceae: Focus on azithromycin

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this